Fresenius Kabi, Insud Pharma and other generic drug firms
explain how the EU’s SPC manufacturing waiver in its compromised form will
benefit them – but also how its notification clause could make litigation
easier and more attractive to innovator drug companies. (Read more … )
Uber, Nestlé and a luggage company speak to Patent Strategy about their due diligence difficulties during mergers and acquisitions and how they avoid the inherent portfolio analysis pitfalls. (Read more … )
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.